> News > AC BioScience closes fourth Seed Round for CHF 2.5M
26.08
2022

AC BioScience closes fourth Seed Round for CHF 2.5M

AC BioScience, a Biopôle-based clinical stage biotech company, is pleased to announce the successful closure of a fourth Seed Round for CHF 2.5 million. The company is pioneering the development of novel therapies in immuno-oncology and tumor vascular normalization with the first exploratory clinical trial Phase 2a for metastatic pancreatic cancer patients to start in early 2023. This bridge funding precedes a Series A Round to fund the planned clinical trials for our two lead investigational drugs.

Read more on startupticker.ch

Company related to the news